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Abstract
Gene therapy is an emerging alternative to conventional anti-HIV-1 drugs, and can potentially control the virus while
alleviating major limitations of current approaches. Yet, HIV-1’s ability to rapidly acquire mutations and escape therapy
presents a critical challenge to any novel treatment paradigm. Viral escape is thus a key consideration in the design of any
gene-based technique. We develop a computational model of HIV’s evolutionary dynamics in vivo in the presence of a
genetic therapy to explore the impact of therapy parameters and strategies on the development of resistance. Our model is
generic and captures the properties of a broad class of gene-based agents that inhibit early stages of the viral life cycle. We
highlight the differences in viral resistance dynamics between gene and standard antiretroviral therapies, and identify key
factors that impact long-term viral suppression. In particular, we underscore the importance of mutationally-induced viral
fitness losses in cells that are not genetically modified, as these can severely constrain the replication of resistant virus. We
also propose and investigate a novel treatment strategy that leverages upon gene therapy’s unique capacity to deliver
different genes to distinct cell populations, and we find that such a strategy can dramatically improve efficacy when used
judiciously within a certain parametric regime. Finally, we revisit a previously-suggested idea of improving clinical outcomes
by boosting the proliferation of the genetically-modified cells, but we find that such an approach has mixed effects on
resistance dynamics. Our results provide insights into the short- and long-term effects of gene therapy and the role of its key
properties in the evolution of resistance, which can serve as guidelines for the choice and optimization of effective
therapeutic agents.
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Introduction
With no HIV-1 vaccine or cure in sight, treating and controlling
the virus continues to be a major global health concern [1,2]. The
advent of highly active antiretroviral therapy (HAART) has
remarkably prolonged patients’ survival, but has failed to eradicate
the virus or to control the epidemic. In particular, HAART is a
lifelong treatment, and as such presents major obstacles, including
cumulative toxicities, severe side effects, a strict and complicated
regimen, and problematic economics. Its major problem, however,
is HIV-1’s ability to escape it by developing drug-resistant
mutants, which is further worsened by poor patient compliance
[3]. Currently, the pace of development for new therapies lags
behind HIV’s rapid evolution of drug resistance, and alternative
approaches are sought to either complement or replace HAART.
Gene therapy is an emerging and promising approach to
treating HIV-1 infection, whereby engineered genes are delivered
ex vivo, and potentially ultimately in vivo, into a patient’s cells. They
then act within these cells to disrupt the viral life cycle. Gene
therapy offers the potential to attain sustained viral suppression
and a restored immune system, with the added advantage of a
simplified regimen, very few medical interventions, and reduced
toxicities. To date, a plethora of potent gene-based inhibitors have
been developed in the lab and some have undergone early-phase
clinical trials (reviewed in [4]). While the trials demonstrated safety
and feasibility, the infused gene-modified cells did not accumulate
with time and consequently could not exert meaningful clinical
effects [5,6,7]. Achieving therapeutic proportions of gene-modified
cells in vivo is thus a necessary preliminary step for gene therapy’s
success. Ultimately, however, this approach must prove efficacious
in the presence of viral resistance in order to qualify as a feasible
therapeutic option. Indeed, as with HAART, viral escape is
presently a major concern in the design of any gene-based
technique [8,9,10,11], and combinatorial gene cassettes are
commonly developed as a means of limiting escape [12,13,14].
While the qualitative relations between key design parameters and
viral escape are generally understood, a more rigorous quantitative
investigation is essential to better understand the parameters’ long-
term effects under clinically-relevant conditions. The focus of this
work is on a computational modeling approach to illustrate the
contribution of therapy parameters and strategies to delaying the
emergence of resistant virus in a patient.
Modeling HIV dynamics is by now a well-accepted tool for
elucidating mechanisms of interest and for understanding viral
evolution [15,16,17,18]. A great deal of work has been published
with regards to HAART, and has had much success largely due to
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its clinical validation against patient data. For novel treatments like
gene therapy, however, substantial clinical data is not yet
available. One must then resort to theoretical investigation as a
much-needed step in therapy design. However, very few models
have explored viral dynamics under gene therapy, and these have
focused primarily on the response of virus that is sensitive or not
resistant to the therapy [19,20,21]. Interestingly, this work
revealed major deviations from HAART-like dynamics, thus
underscoring a need for a dedicated model of viral resistance
under gene therapy conditions.
Leonard et al. [22] developed a stochastic in vitro model that
elucidates HIV’s escape from RNA interference (RNAi) gene
therapy. While powerful for studying escape in vitro [23], the model
has several features that limit its relevance to in vivo scenarios. First,
it focuses on RNAi therapies that degrade viral transcripts, an
intervention that occurs after a cell has been infected and may thus
not facilitate sufficient outgrowth of the gene-modified cells in vivo,
as was later suggested in [21]. Conferring the modified cells with
substantial outgrowth capacity is essential in any practical setting
due to severe limitations on the fraction of cells that can be
genetically modified [24,25]. Other properties that diverge from in
vivo conditions include simulations that often predict complete viral
eradication [19,21], and small population sizes that might under-
represent minority viral strains [26,27]. Since sustained viral
replication and pre-existing mutants both play a crucial role in
fueling resistance, they should be included in an in vivo model.
Recently, von Laer et al.’s study [21] suggested that genes which
inhibit early stages in the viral life cycle (by preventing cell
binding, membrane fusion, reverse transcription, or integration)
have the capacity to propel major cell expansion and therapeutic
benefit. A variety of suitable gene-based techniques can be used,
including RNAi- [28,29], ribozyme- [13], zinc-finger nuclease-
[30], and antibody-mediated [31] disruption of the CCR5 co-
receptor, expression of fusion-inhibitory and binding-inhibitory
peptides and of single-chain antibodies [32], and interference with
capsid uncoating [33].
In this study, we developed a hybrid stochastic-deterministic
approach for describing the evolution of HIV’s resistance to early-
stage gene-based inhibitors in vivo. We extended prior modeling
work [19,21] to incorporate a diverse viral population entailing
varying degrees of sensitivity to therapy, and to account for the
random effects that dominate early phases of resistance develop-
ment. Our aim is to provide a general model that captures the
commonalities of a broad range of technologies and that can be
further adapted to faithfully describe any specific treatment. We
apply the model to elucidate the general principles that govern
resistance evolution and present extensive simulation results that
quantify the tradeoffs between controllable therapy parameters.
We show that the fundamentally different dynamics under gene
therapy suggest different design guidelines from HAART’s.
Specifically, unlike HAART, in which drugs provide nearly-
homogeneous protection to most cells, protected (gene-modified)
and unprotected (untreated) cells co-exist under gene therapy. We
find that this property can be harnessed to impede escape,
provided that the mutations are associated with non-negligible
fitness losses in non-modified cells.
We also investigate a novel delivery strategy to combat
resistance, whereby different genes that target different viral
functionalities are delivered into separate cell populations. Model
simulations indicate that under some conditions, this idea, which is
uniquely applicable to gene therapy and has not been analyzed
previously, can dramatically prolong viral suppression and
decrease the likelihood of escape. Finally, we study the
development of resistance when the gene-modified cells have a
proliferative advantage over untreated cells. Simulations demon-
strate mixed implications on viral escape, namely, that it is less
frequent but that when it does occur, it occurs more rapidly. The
presented work provides a basic and general understanding of the
key characteristics of gene therapy and their role in the evolution
of resistance. Model predictions thus offer guidelines to optimizing
therapy for long-term suppression of HIV-1 in patients.
Results
Motivating Data
Gene therapy is still a nascent technology; however, there have
been a number of studies that serve to motivate our model. Here,
we briefly outline the methodology and findings of several studies
and discuss how our modeling work was inspired by them.
The first study is a phase I trial in which CD4+ T cells were
harvested from five HIV-positive patients, transduced ex vivo with a
lentiviral vector expressing an antisense RNA targeting HIV,
amplified, and then infused back to the patients [5]. The patients
were followed for several years, throughout which their immuno-
logical function and the persistence of the gene-modified cells were
assessed. This trial not only demonstrated long-term survival of
these cells in vivo, but also showed sustained and statistically
significant reductions in the viral load in several patients.
However, the modified cells declined in number following the
infusion, and persisted at frequencies lower than 1% for most of
the trial duration. These findings suggest that the cells are
imposing some sort of selective pressure on the virus, although
their mechanism of action is currently unclear as gene modifica-
tion frequencies were too low to account for the observed changes.
As we mentioned earlier, current transduction efficiencies are
low, implying that the modified cells must accumulate in vivo to
reach therapeutic numbers. Such trend has not yet been observed
in early-phase anti-HIV trials [24], indicating that the selective
advantage of these cells in vivo is not sufficiently high. This may be
because the engineered genes or their products lose their activity in
vivo, and/or because the cells’ proliferative capacity was impaired
during their ex vivo manipulation. Current attempts to tackle these
Author Summary
A primary obstacle to the success of any anti-HIV
treatment is HIV’s ability to rapidly resist it by generating
new viral strains whose vulnerability to the treatment is
reduced. Gene therapies represent a novel class of
treatments for HIV infection that may supplement or
replace present therapies, as they alleviate some of their
major shortcomings. The design of gene therapeutic
agents that effectively reduce viral resistance can be aided
by a quantitative elucidation of the processes by which
resistance is acquired following therapy initiation. We
developed a computational model that describes a
patient’s response to therapy and used it to quantify the
influence of therapy parameters and strategies on the
development of viral resistance. We find that gene therapy
induces different clinical conditions and a much slower
viral response than present therapies. These dictate
different design principles such as a greater significance
to the virus’ competence in the absence of therapy. We
also show that one can effectively delay emergence of
resistance by delivering distinct therapeutic genes into
separate cell populations. Our results highlight the
differences between traditional and gene therapies and
provide a basic understanding of how key controllable
parameters and strategies affect resistance development.
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issues focus on increasing the vector-copy numbers per cell, and on
intensive development of culture systems that better enrich and
maintain T cell subsets which display extensive replicative capacity
(reviewed in [34,35]). Encouraging results from two recent studies
are also worth noting. In one study, cells modified with zinc-finger
nucleases expanded to therapeutic levels and induced substantial
clinical effects in a mouse model of HIV infection, thus
demonstrating their efficacy and selective advantage [30]. A
clinical trial to test this approach in humans is currently underway.
In a second study, the long-term (i.e., two years) expression of
therapeutic genes in human blood cells in vivo was confirmed [36].
Clearly, the enabling technology is yet to mature, but once these
barriers are overcome and gene therapy enters the clinic, viral
resistance is to become the major concern. This is the starting
point to our study, and one of our goals is to understand the
implications of a potent gene therapy on viral evolution and what
may be done to prolong its therapeutic effects in the presence of a
rapidly mutating virus.
Another noteworthy phase I trial is a very recent one, in which
CD34+ hematopoietic progenitor cells of four patients were
transduced with a lentiviral vector expressing a combination of
three unique gene therapies [36]. While combination therapy
similar to HAART has been promoted in the gene therapy field as
a method for combating viral escape, this is the first trial to put this
idea into practice. In this trial, all three therapies were expressed
from the same vector, a technique that provides the highest levels
of protection in each cell, but also requires significant optimization
and is subject to constraints. Given that more combination
therapies will likely be developed, we asked how effective such
combinations are in maintaining long-term viral suppression.
Furthermore, gene therapy opens up a unique opportunity to split
such combinations across cells, such that some cells express one
therapy and others express another therapy. Such approach may
offer an appealing and less technically demanding alternative to
current combinatorial approaches. Here, we aim to explore its
potential to provide significant improvements in preventing
escape.
Model Overview
The model consists of two types of susceptible CD4+ T cells:
transduced cells that are infused to the patient (protected (P) cells),
and naturally occurring cells that were not manipulated
(unprotected (U) cells). The overall CD4+ T cell pool is
maintained by homeostatic proliferation, which saturates accord-
ing to Michaelis-Menten kinetics (Figure 1A) [37]. Both cell types
are regulated by the homeostatic mechanism in the same manner,
and contribute equally to saturation, thus equally competing for
presence in the pool. The renewal of susceptible cells is assumed to
rely mainly on self-proliferation, with additional minor contribu-
tion from the bone marrow, modeled as a constant export of
mature cells from the thymus. In this work, we focus on delivery of
T cells, as opposed to stem cells, and hence the bone marrow
Figure 1. Schematic illustration of infection dynamics under
gene therapy and of the development of resistance to it. (A)
Diagram of the baseline model, which considers only a single sensitive
viral strain. Two types of T cells are considered: gene-modified cells
which are protected from infection (shown in red) and non-modified
cells that are susceptible to it (shown in blue). The proliferation rate of
both cell populations is determined by a saturating function, g(UzP),
which takes a Michaelis-Menten form. Therapy effects are conveyed via
an infectivity inhibition factor (e) for gene-modified cells. (B) An example
of a possible evolutionary path towards the emergence of a highly
resistant strain. A genetic barrier n~3 corresponds to a set of three
resistance-conferring sites (hashes), where any combination of these
sites can be mutated (stars). At each integration step of the simulation,
a strain may only accrue a single mutation in one of the non-mutated
sites. The degree of resistance is determined by the number of
mutations (m), and is manifested as improved infection of P cells (i.e.,
higher infection rates due to an increase in e). Mutations are also
associated with a loss in fitness that negatively affects the ability of
these mutants to infect U cells, and that also depends on the number of
mutations.
doi:10.1371/journal.pcbi.1000883.g001
Model of HIV-1 Resistance to Gene Therapy
PLoS Computational Biology | www.ploscompbiol.org 3 August 2010 | Volume 6 | Issue 8 | e1000883
engenders only U cells. HIV infection dynamics follow standard
HIV models [16,17,38], with the therapy effects manifested as an
inhibition of viral infectivity of the P cells.
The model considers a viral population consisting of a sensitive
wild-type (WT) strain as well as other strains to which WT may
evolve through a series of mutations. There are n genomic sites
that confer resistance to therapy, and each mutant strain can have
any combination of them mutated away from their WT form.
Resistance is assumed to gradually intensify with increasing
numbers of mutated sites, and it manifests as an improved ability
to infect P cells, but is at the same time associated with a fitness
cost when infecting U cells (Figure 1B). The model captures all
interactions via ordinary differential equations (ODE), but uses a
stochastic routine to treat populations at low densities, such as
those of newly-emerging species (see the Methods section for
details).
Viral Dynamics in the Absence of Resistance
We start by exploring a restricted baseline model, similar to the
model of Lund et al. [19], in which resistant strains are absent. We
use it to demonstrate the inherent differences between gene
therapy and HAART and to quantify the effects of different
parameters on the achievable viral suppression levels.
Figure 2A shows in vivo dynamics following a P cell infusion, as
simulated with default parameter values (see the Methods section).
The P cells are shown to expand, thereby impeding the supply of
U cells and thwarting viral replication. The establishment of a P
cell reservoir brings the virus to a new reduced set point. The P
cells’ expansion is driven by a selective advantage they possess over
U cells, which derives from a reduced susceptibility to infection.
The expansion thus slows down as the viral load declines.
In comparison to post-HAART behavior [39,40], three
substantial differences are clear: the heterogeneity of the target-
cell population, the slow nature of the response, and the limited
reduction in viral load. In particular, HAART blocks viral
replication on nearly the entire target-cell population, resulting
in a rapid viral decline. This is in contrast to our model, where the
U cells experience only a slight decline, and continue to facilitate
viral replication, albeit at lower volumes due to their reduced
turnover rates. In addition, HAART takes effect promptly and
comprehensively, whereas gene therapy induces a gradual
depletion of the U-cell supply, fueled by the inherently slow
process of P cell accumulation. To summarize, the two approaches
Figure 2. Infection dynamics under gene therapy and the
dependence of the viral suppression gain on the inhibition
factor and on the thymus contribution. (A) Dynamics in the
absence of viral resistance. Simulations were performed with default
parameter values (see the Methods section). (B) The suppression gain
(G) is the ratio between the viral loads in the pre-therapy and post-
therapy steady states of the baseline model (see the Methods section
for an explicit expression). It depends linearly on the inhibition factor e
(x-axis) and is depicted on a logarithmic scale. The inset (depicted on a
linear scale) demonstrates that decreasing the inhibition factor below a
few percent has negligible contribution to viral suppression. The pre-
therapy steady state becomes the stable solution when e is
approximately 0.98 (not shown). All parameters were set to their
default values (see the Methods section). (C) The thymus’ relative
contribution (x-axis) is the fraction of the total T-cell mortality that is
replaced by the export of mature cells from the thymus, as opposed to
by self-proliferation of the T-cell pool. The suppression gain is inversely
proportional to it and diminishes quickly. HAART-like gains may be
achievable only for diminutive relative contributions. When the
contribution is sufficiently large, no viral reduction is obtained, and
the pre-therapy steady state becomes the stable solution (not shown).
In order to keep the pre-therapy conditions fixed for all points, the
proliferation rates and parameters were adjusted to compensate for a
varying thymus input. Other parameters were set to their default values
(see the Methods section).
doi:10.1371/journal.pcbi.1000883.g002
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exhibit different mechanisms of action: brute-force disruption of
viral activity by blocking access to existing resources (HAART)
versus draining the supply of those resources in favor of more
robust ones (gene therapy). Since gene therapy profoundly re-
structures the blood system to render it less susceptible to HIV, it is
slow to exert its effects. Yet, only innate changes of this kind can
facilitate sustained virus control with limited medical intervention.
HAART, on the other hand, is quick to act, but once interrupted,
results in immediate viral rebound and thus necessitates a strict
lifelong adherence to an elaborate drug regimen.
Therapy efficacy. We developed metrics and analysis to
quantify the therapy’s potency in suppressing the virus. Within this
work, we assumed that infectivity is inhibited by a factor of
0vev1. We further assumed that virion production in infected P
cells is completely eliminated, which can be realized by inserting
additional antiviral genes that target late stages of the infection
[4,41,42,43]. Importantly, both infectivity inhibition and progeny
suppression contribute similarly to disrupting viral replication [39];
however, the former is essential to the expansion of P cells,
whereas the latter does not confer them with any selective
advantage. Due to very low dosages of infused cells, progeny
suppression alone would only exert a weak and transient effect
[21]; however, by providing a selective advantage to modified
cells, infectivity inhibition allows the P cells to reach therapeutic
levels and, in combination with progeny suppression, provide the
latter with the opportunity to further disrupt HIV [21]. This can
be thought of as an ‘‘ideal’’ best-case scenario, which elucidates the
ultimate potential of infection inhibition. We also compared the
ideal case to the baseline case, where virion production is
unaffected (Figure 1A), and found that for currently plausible e
values (a few percent or less [10,44]), the differences in dynamics
were negligible. We thus performed steady-state analysis of the
best-case model and found that despite the complex suppression
mechanism, the degree of viral reduction depends only on three
parameters: the inhibition factor e, the thymus-input rate l, and
the infected-cell life span d (see the Methods section for explicit
expression).
We define the suppression gain G to be the ratio between pre-
therapy and post-therapy steady-state viral loads, and the
expression for this metric (see the Methods section) enables
analysis of the system’s dependencies on key parameters.
Interestingly, G depends linearly on e, as illustrated in Figure 2B
(note that G is depicted on a logarithmic scale). It ranges between a
maximum of nearly two logs at e~0 and zero at e very close to 1.
From a therapy design perspective, the important point here is
that there is negligible incremental benefit for highly potent
inhibition, especially when going below the reasonably achievable
levels of a few percent [10,44] (shown in the inset). This finding
echoes previous predictions that were derived from different
models [21]. However, as we shall see later, potent inhibition is
instrumental in controlling viral resistance and hence should not
be overlooked.
In addition, G has an inversely-proportional dependence on l
(Figure 2C). In Figure 2C, l is expressed in terms of the thymus’
relative contribution to overall T cell renewal, a measure that is
proportional to l. One can see that significant gains are achievable
for extremely small thymus contributions, but they quickly
diminish up to a point of no viral reduction, in which case the
post-therapy set point becomes unstable. This indicates that the
bone-marrow contribution can significantly undermine the ability
to achieve considerable viral declines. Although its relative
contribution is known to decay with age and to account for a
small fraction of the T cell renewal in adults, l has not been
accurately quantified to date, and current estimates range from a
tiny fraction to more than one tenth [45,46,47,48]. Quantifying l
thus constitutes an important step in understanding the potential
clinical benefits and limitations of a T-cell based approach. A
possible way to circumvent such limitations is by enhancing the P
cells proliferative capacity [21], and we will examine it later from
the viewpoint of viral resistance.
Emergence and Fixation of Resistant Mutants
The integration of resistance into our model gives rise to an
additional therapy characteristic, namely, a genetic barrier n,
which we define as the number of mutations that the virus must
accumulate in order to completely overcome inhibition by P cells
(Figure 1B). To preserve the simplicity and tractability of the
model, we assumed that a mutant’s phenotype is determined by
the number of accumulated mutations, but not by their actual
identity or location (see the Methods section). In other words,
strains that possess different combinations of m mutations are
phenotypically indistinguishable. Our model limits the mutational
effects to modified infection rates (i.e., varying attenuations of
WT’s infection rate) for two reasons. First, this is the most likely
route to escape [10]. Second, it is the most effective one, since once
the P cells expand and the increased infection rates allow the virus
to infect significant portions of them, only then virion production
can exert meaningful effects. As gene therapy involves two cell
populations, the model accounts for contradicting effects on both
cell types, as follows. On one hand, resistance confers the virus an
improved ability to infect P cells, while on the other hand, the
accumulation of mutations in key regions of the virus targeted by
the therapy can also be associated with a reduction in fitness in the
absence of therapy, that is, in U cells [23,49,50,51,52]. The model
assumes that both effects gradually escalate with each additional
mutation [10,50,52,53,54]. Since our model attempts to broadly
apply to several techniques, it perceives the genetic barrier as a
general property and disregards its specific origins. A large n may
thus correspond to several inhibitors acting concomitantly, or to a
single inhibitor whose interaction with the virus spans a large
domain [10]. A similar interpretation applies to the inhibition
factor e.
We performed stochastic simulations with our model and
aggregated the mutants’ densities according to number of
mutations, such that all strains with m mutations (0ƒmƒn) count
as one species. Figure 3 shows the outcome of a typical simulation
of the stochastic trajectory when n~6. It demonstrates an
accumulation of increasingly fitter mutants at the expense of less
competent pre-existing (e.g., m~1, 2, 3) and early-appearing
mutants (e.g., m~4). Mutants that possess higher numbers of
mutations (e.g., m~5) are increasingly more competent, and
eventually reach levels that give rise to even fitter strains (e.g.,
m~6), which soon outgrow them. In the presence of highly
resistant strains, the P cells lose their advantage and decline (not
shown). Note that the decline of pre-existing mutants with one or
two mutations is a consequence of both the drop in the WT viral
population, which continuously feeds the mutants populations,
and of their susceptibility to therapy. However, the decline is slow,
thereby constituting a major obstacle for gene therapy, as it fuels
progressive mutation accumulation and expedites the emergence
of non-existing resistant strains. In contrast, under HAART, pre-
existing strains swiftly drop to very low levels, and while still
present, their mutation into more resistant strains is severely
confined by their small absolute numbers.
The stochasticity that arises from the random effects that
dominate at small population sizes can be seen for existing mutants
with three mutations and for newly emerging mutants. New
advantageous mutations occur at random and may drift away
Model of HIV-1 Resistance to Gene Therapy
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before reaching critical levels, thereby delaying emergence in
comparison to fully-deterministic trajectories [18]. As delays build
up along the evolutionary process, larger n’s are progressively
associated with increasingly varying fixation times of highly
resistant strains (see Figure S1). As a result of this stochasticity, it
is striking that two ‘‘identical’’ patients (i.e., infected with the
‘‘same’’ virus) can experience remarkably different clinical
outcomes.
As a measure of the treatment’s efficacy, we computed the
fixation time, defined as the time required for the resistant strains
to reach 50% of the viral population. Treatment was considered
successful if fixation had not occurred within four years of its
initiation. Figure 4A–4C provides an overview of the three figures
of merit by which we evaluate a treatment. Each point in the plots
summarizes the results of 500 simulations with default parameter
values (see the Methods section). The blue curves correspond to a
standard application of gene therapy, as discussed above, whereas
the red curves correspond to a more advanced strategy and will be
discussed in a later subsection. At this point, we limit discussion to
the blue curves. Figure 4A shows how the fraction of successful
treatments, called the success rate, varies with the genetic barrier n.
Interestingly, success rates exhibit a threshold-like behavior, which
was found to be typical with many other parameter choices (not
shown). Such an effect becomes important when one considers
combining several gene-based inhibitors within a P cell as a means
of increasing n. If a therapy is near the threshold, the addition of
an inhibitor can make a dramatic difference in its efficacy.
Figure 4B shows average fixation times for all n’s for which
therapy success rates were below 0.9 (see Figure 4A). As expected,
larger n’s result, on average, in prolonged viral suppression.
Figure 4C shows the average of the corresponding viral load
reductions (i.e., the inverses of the suppression gain) obtained at
the fixation time. One can see that the average viral reduction
keeps declining until n~6,7, reflecting the fact that for nv6,
resistance emerged before therapy has reached its steady state in
the absence of resistance. This implies that under our default
parameter choices, even considerable genetic barriers (e.g.,
n~4,5) do not suffice to allow therapy to reach its full suppression
potential before resistance emerges.
Finally, we wish to stress that the inhibition factor e is assumed
to be independent of n and thus was kept fixed throughout
simulations. Specifically, a larger n does not imply a stronger
inhibition, even when obtained through insertion of additional
genes. The dynamics under gradually increasing inhibition can be
readily obtained using similar simulations.
Replication Fitness over a Heterogeneous Target
Environment
The notion of replication fitness has long been used for
understanding HIV’s evolution under HAART [55,56,57,58]. It
is a model-derived measure of a strain’s ability to expand over time
in a given environment, and provides a tool for understanding and
predicting clinical outcomes. This measure, however, was derived
from HAART models and does not apply to gene therapy,
whereby HIV is faced with a mixed cell composition and may
display different replication traits within each cell subpopulation.
We used our model to extend this notion to the case of a
heterogeneous target-cell environment (see the Methods section
Figure 3. Dynamics of resistance evolution in a typical hybrid stochastic-deterministic simulation. Following T cell infusion, a decline in
wild-type (WT) virus and pre-existing mutants is accompanied by the emergence of fitter and highly resistant mutants. Mutant strains are aggregated
according to the number of resistance mutations they carry (m), which determines their resistance phenotype. Carrying more mutations renders a
strain more resistant, with the most resistant strain carrying n=6 mutations. Stochastic effects are observed at very low densities, where
advantageous mutations experience drifts before accumulating to critical levels which enable their consistent expansion. Populations whose density
decreases below a pre-defined threshold (3|10{9 entities per mL) are considered extinct until they resurface. In this simulation, the total mutant
density reaches WT density at approximately 550 days after infusion, marking the fixation of the resistant strain. Simulation was performed with
default parameter values (see the Methods section).
doi:10.1371/journal.pcbi.1000883.g003
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and Text S1 for derivation). The replication fitness (F) of a strain
M is captured by the following expression:
F~wM~k(UzeMP){d ð1Þ
where U and P are the two cell-type densities, ~k is a generalized
infection rate constant (see the Methods section), d is the infected
cells’ death rate, wM is a replicative fitness cost associated with
mutating, and eM is the infectivity-attenuation factor. The
parameters wM and eM summarize the cost and benefit involved
in viral escape, and are determined by the number of mutations in
strain M, as well as by the therapy’s potency (e) and genetic barrier
(n) (see the Methods section and Figure 1B). The parameters ~k and
d, in contrast, are unaffected by viral evolution, and so distinct
viral strains feature different wM and eM , which, when weighted
through Eq. (1), yield an overall replication fitness. Importantly, U
and P are time dependent, and so F varies as therapy progresses.
Yet, changes to U are minor in our model, and P transiently
increases until it saturates.
Eq. (1) encapsulates the key determinants of viral resistance and
provides insights into therapeutic design tradeoffs. We illustrate this
point with a simple example. Consider a potent therapy that inhibits
WT’s infectivity with eWT~0:001 (Figure 1A), and suppose that the
U and P cell densities both equal 500 cells/mL. The WT virus’
fitness is then given by (500z0:001|500)~k{d~500:5~k{d.
Consider two strategies to weaken the virus: applying a tenfold-
stronger infectivity inhibition (e0~0:0001) or interrupting its normal
function such that it experiences a modest fitness loss of
5% (w0~0:95) but the same inhibition as before (e~0:001).
The corresponding changes to the replication fitness amount
to{(0:001{0:0001)|500~k~{0:45~k in the first case, compared
to a more favorable {0:05|500:5~k&{25~k in the latter case.
Even starting with eWT~0:01 and applying a 100-fold decrease
(yielding the same e0) attains only a decrease of 5~k in the first case,
which is somewhat more comparable to the losses from the
moderate 5% replicative cost. Clearly, realistic tradeoffs depend on
the U and P densities as well as on simultaneous changes in all
parameter values, but this example stresses the different impact of w
and e on controlling viral replication. It shows that viral fitness in the
U cell pool plays an important role in restraining replication,
provided that mutations are associated with a replicative cost, and
that powerful protection in P cells has a modest contribution in
comparison. Next, we use simulations to show that modest fitness
Figure 4. Quantitative evaluation of treatment strategies
investigated in this study. Each point summarizes the average
outcome of 500 simulations with default parameter values (see the
Methods section). The blue curves correspond to a standard use of a
single gene therapy (discussed in subsection ‘‘Emergence and Fixation
of Resistant Mutants’’). The red curves correspond to a combination-
therapy strategy whereby the P cells are divided into two sub-
populations, each protected by a distinct set of genes (discussed in
subsection ‘‘Divide and Conquer – an Effective Strategy to Combat
Resistance’’). (A) Effects of increasingly larger genetic barriers n (x-axis)
on the fraction of successful treatments (y-axis), featuring a threshold-
like behavior. A treatment is considered successful if mutant fixation did
not occur within four years after its initiation at day 0. (B) Effects of
increasingly larger genetic barriers n (x-axis) on the average time to
fixation (y-axis), which is the time required for the resistant strains to
reach 50% of the viral population. Data are depicted only in cases
where the success rates are below 0.9, representing at least 50 fixation
events per point. (C) Effects of increasingly larger genetic barriers n (x-
axis) on the average viral reduction at the time of fixation (y-axis),
depicted when success rates are below 0.9. The viral reduction is the
ratio between the viral loads at fixation time and at day 0. Large genetic
barriers are needed in order for the therapy to reach its set point before
resistance emerges. (A,B,C) Viral suppression under the two-therapy
regimen is gradually prolonged throughout the entire barrier range,
and displays a dramatic advantage at n~5 (B). Success rates and viral
reduction are also improved (A,C).
doi:10.1371/journal.pcbi.1000883.g004
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penalties can impede resistance as effectively as major increases in
potency.
Effects of Fitness Cost and Inhibition Potency
To further explore the roles of mutational fitness cost and
inhibition potency in controlling resistance, we simulated the
model over a wide range of parameters. We first varied the
average fitness cost that the virus incurs with each additional
mutation (w), while fixing all other parameters at their default
values. Figure 5A–5B shows success-rate and fixation-time graphs,
spanning a range of fitness costs. As expected, greater fitness
penalties hamper escape and shift the ‘‘success threshold’’ towards
lower n’s. Increased penalties also delay therapy failure (fixation
time), allowing for greater viral reductions (not shown). One can
also see that it is essential for gene therapy to target viral
functionalities for which resistant mutations incur non-negligible
costs (wv0:98).
The effects of altering the inhibition factor e are shown in
Figure 5C–5D for two fitness costs. Here, the inhibition was amplified
tenfold each time, resulting in meaningful improvements. It can be
seen that when mutational fitness costs are minor (w~0:98), highly
potent inhibition is needed to effectively hamper resistance, as this is
the only way to restrain the virus. The tradeoffs between the two
factors are exemplified by the two sets of nearly overlapping curves
(shown in dashed lines), which correspond to a tenfold increase in
inhibition coupled with a slight decrease in fitness cost.
While mutational fitness cost for viral replication in the U cell
pool appears to dominate resistance dynamics, our simulations
also indicate that powerful inhibition can in fact control the virus,
and constitutes an important design criterion. It takes effect by
weakening early mutants, such that for a given n, more mutations
are needed to reach a sufficiently fit virus. One means to achieve
increased potency may be through combination therapy, provided
that the individual effects are multiplicative. Nonetheless, to the
best of our knowledge, the incremental contributions of single
therapies within an ensemble have not been determined to date.
Divide and Conquer – An Effective Strategy to Combat
Resistance
Combination therapy has traditionally been the treatment of
choice against the rapidly mutating HIV-1. Simultaneous
targeting of several functional domains slows down resistance by
concurrently increasing the genetic barrier and strongly suppress-
ing replication. Gene therapy adopted this principle [12,13,41],
but more importantly, opened the door to a new combination
strategy that has hitherto been infeasible, that is, of combining
targets across cell populations as opposed to within individual cells.
Ex vivo gene transduction provides the clinician with control
over the destination of delivered drugs, which, in turn, enables the
infusion and in vivo expansion of distinct P cell pools, each
containing different inhibitors that target distinct viral function-
alities. In this setting, a strain that resists one inhibitor is confined
Figure 5. Effects of altering the fitness cost and the inhibition potency on therapy efficacy. Success rates (fractions of successful
treatments) and average fixation times are shown as functions of the genetic barrier n (x-axis) for a range of mutational fitness costs w (A,B) and for a
range of inhibition factors e (C,D). The data summarize the outcomes of 500 simulation runs per each parameter set, similar to Figure 4. In each panel,
different colors are used to depict different parameter values, with black depicting the default case. The plots demonstrate that increasing the fitness
cost (lowering w) and decreasing the inhibition factor e both result in prolonged viral suppression. This is manifested in improved success rates and in
delayed resistance emergence. Panels C and D depict the effects of varying the inhibition factor for two distinct fitness costs (w~0:95, 0:98),
illustrating the tradeoff between the two factors. It can be seen that a tenfold increase in inhibition (e~0:01?e~0:001, w~0:98) is as effective as a
slight decrease in fitness cost (e~0:01, w~0:98?w~0:95). Panels C and D also point out that minor fitness costs (e.g., w~0:98) must be
compensated by powerful inhibition (eƒ0:001) in order to attain long-term suppression with potentially achievable genetic barriers (nƒ8).
doi:10.1371/journal.pcbi.1000883.g005
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to replicate only on a fraction of the P cell population, and is still
suppressed within the rest of it until it acquires additional
mutations. The idea, then, is to limit the resources available to
the evolving virus by forming sub-populations of P cells.
We illustrate this principle and explore its potential using a
computational model (see the Methods section and Text S1). Since
this strategy can be used on top of any gene therapy technique, it
represents an additional mechanism to combat resistance. We thus
seek to quantify its added value compared to using homogeneous
protection. Our model considers two gene therapies, P1 and P2,
targeting distinct viral functions such that cross-resistance between
them is excluded. This may apply, for example, to binding and/or
fusion inhibitors (P1) combined with integrase and/or reverse-
transcriptase inhibitors (P2). Both therapies are modeled as equally
powerful - they display the same n and same e, and each may
correspond to one or to several concurrent inhibitors. When
introduced into two cell populations, they divide the P cells into
two smaller sub-populations and give rise to a complex
quasispecies environment with viral strains that display a range
of resistance levels to one or both therapies. The baseline case, as
captured by the previously discussed model, corresponds to use of
just one of these therapies.
The resulting average fixation times and success rates were
compared to their single-therapy counterparts (Figure 4A–4B). We
found that fixation times improved gradually (but modestly)
throughout the entire range, until a dramatic increase in favor of
therapy combination took place at n~5 (Figure 4B). The same
effect is manifested as a meaningful shift in the success-rate curve
in favor of combination therapy - it suffices to use two therapies
with n~6 as opposed to n~8, which is required for a successful
stand-alone approach (Figure 4A). Figure 4 pertains to simulations
performed with default parameter values, but we observed the
same trend for a wide range of other parameter values, with some
variation in the position (n) of the dramatic shift (data not shown).
Simulations with three distinct therapies showed further improved
gains at all levels, as expected (data not shown). We conclude from
our findings that this approach is powerful when used judiciously
within the ‘‘right’’ n range.
To Split or Not to Split – Comparison of Combinatorial
Strategies
Another interesting question is how the added value of splitting
therapies across cells compares with the added value of increasing
the genetic barrier. This question is of significance to gene therapy,
where large n’s are necessary to guarantee long-term suppression
(Figure 4). Large barriers will likely be accomplished through
combinatorial approaches (within each cell), which in turn, are
associated with technical and physiological challenges [59,60] that
may consequently limit the achievable barriers. This is especially
relevant to RNAi therapy, which is characterized by low
individual barriers and strongly relies on combinatorial approach-
es, but at the same time, faces serious obstacles associated with
multiple payloads [61]. In light of these challenges, splitting
therapies may offer an alternative to pursuing large multi-
component payloads.
We used our model to answer the following question: is it more
beneficial to use two therapies whose genetic barrier is n or to
invest the effort to design one therapy with an enhanced barrier
nz1? We show that there is not a definitive answer to this
question, as illustrated in Figure 6A for n~4. Average fixation
times under both strategies are depicted for a range of inhibition
factors e, where each case resulted in a different answer. The
‘‘splitting strategy’’ appears to perform slightly better in the
presence of a relatively weak therapy (e~0:1), but loses its
advantage under more potent regimens. Similar situations were
observed for other n values (data not shown).
We interpret our ambiguous results by examining the viral
replication fitness (Eq. (1)) under both conditions. Consider a
resistant strain M whose replication fitness equals
wM~k(UzeMP){d. When two therapies are split across cells,
Figure 6. Efficacies of different combinatorial gene therapy strategies. Two strategies are considered: protecting the entire P cell
population with a single gene-based inhibitor whose genetic barrier is n~5, and dividing the P cell population into two sub-populations, such that
each one is protected by a different gene-based inhibitor whose genetic barrier is n~4. (A) The efficacies of the two strategies are compared in terms
of their resultant average fixation times, for three different inhibition factors (e). All other parameters are set to their default values (see the Methods
section). The different relations between fixation times that are observed for different e values suggest that none of the strategies is universally
advantageous. Data are based on the outcomes of 500 simulation runs per each parameter set, similar to Figure 4. (B) The ratio between the
approximate inhibition levels that each strategy exerts on a given strain is depicted (y-axis) as a function of the number of mutations (m) a strain
possesses (x-axis), for each of the three considered e values. The ratio is greater than one when the single-therapy strategy inhibits a strain more
potently than the two-therapy strategy, and vice versa. It can be seen that the ratios correlate with the advantageous strategy, that is, larger ratios
pertain to improved performance of the single-therapy strategy.
doi:10.1371/journal.pcbi.1000883.g006
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one can think of it as downsizing the pool of P cells susceptible to
M by a factor of two, corresponding to a replication fitness of
wM~k(Uz0:5eMP){d. On the other hand, an enhanced genetic
barrier typically renders the mutants less resistant than before the
enhancement, as they now need to overcome additional inhibitory
mechanisms. In our model, this is reflected in a smaller inhibition
factor eM , which should be compared to 0:5eM . An important
point here is that in practice, the extent of decrease from eM to e

M
is case-dependent. Since no pertaining data are currently
available, we determine eM based on simple functional relations
between the inhibition factor and the number of mutations (see the
Methods section). Our results are therefore model-specific, yet
they support our main point that the answer is nontrivial and that
strategies should be compared on a case basis.
We further linked our findings to the suggested interpretation by
computing the ratios 0:5eM

eM when n~4. In our model,
resistance is a function of the number of mutations, giving rise to
five distinct ratios 0:5em

em
 4
m~0
for each case considered, as
depicted in Figure 6B. The considered cases differ in their initial
inhibition potency (e0~eWT ), which determines all intermediate
inhibition factors. The correlation between the ratios and the
advantageous strategy can be readily observed – the more potent a
therapy is (i.e., smaller eWT ), the sooner the ratio curve crosses one,
at which point the single-therapy strategy imposes stronger
inhibition. For example, in the weakest therapy case (eWT~0:1),
the curve is entirely below one, which means that the ‘‘splitting
strategy’’ presents the virus with harsher conditions throughout its
escape route. In the other extreme case (eWT~0:001), a single
therapy exerts stronger inhibition fairly early in the evolutionary
process, even on pre-existing mutants. The middle case shows
mixed effects, which balance out to yield similar fixation times.
In our analysis, we assumed that increasing n has no
implications for therapy potency, or in other words, that e is
independent of n. However, when an increase in n is achieved by
the insertion of additional genes into each P cell, it may be
reasonable to assume that e concomitantly becomes smaller. If we
further assume that e decreased tenfold during the transition to a
larger n, then our simulations indicate that fixation times are
consistently longer for the single therapy regimen (Figure 6A). As
we already emphasized, this might be a model-specific prediction
that may not hold true under other conditions, but we can
certainly state that a simultaneous decrease in e renders the single-
therapy strategy more powerful than before. Finally, we stress that
such scenario-specific results stand in contrast to the comparison
we made earlier, where we found that splitting equally-powerful
therapies across cell populations is always advantageous over using
one of them alone (Figure 4).
Effects of Proliferation Enhancement
As we showed earlier, the potential reductions in viral load
under gene therapy are limited in comparison to HAART
(Figure 2C). Methods to enhance the selective advantage of P
cells by extending their proliferation capacity are being explored,
as a means of boosting their expansion, such that lower viral set
points could be attained. Proposed techniques include expression
of stimulatory interleukins, microRNAs, and telomerase reverse
transcriptase (hTERT) [34,62,63,64,65]. While each technique
carries the risk of uncheck proliferation that could result in cancer
[66], engineering additional safety controls could eventually solve
this problem [34]. We chose to consider the idea of proliferation
enhancement even though the underlying technology is not fully
developed yet, so that we can better understand its impact on the
emergence of resistance.
The potential gains from proliferation enhancement were
previously illustrated by von Laer et al.’s modeling study [21],
and our baseline model displays similar trends of reduction in the
viral load. Since latently infected cells are precluded from the
model, a sufficiently powerful enhancement can in fact eradicate
the virus. It also expedites P cell accumulation, thereby
intensifying the selective pressure on the virus soon after therapy
begins, but at the same time accelerating viral decline (see Figure
S2). Figure 7A–7C shows the outcomes of simulations of viral
evolution under this strategy, with a range of improved
proliferative abilities and with default parameter values. We
modeled enhanced proliferation as a constant percentage increase
in the proliferation rate of P cells with respect to U cells,
represented by a factor aw1 (see the Methods section). We found
that enhancing proliferation consistently expedited the fixation of
resistant strains and, as explained below, seemingly paradoxically
improved the success rates. Overall, the improvements are modest,
and gains diminish with increasing a. The major therapeutic
benefit of this approach is in improved viral reduction before
resistance emerged, despite the faster emergence (Figure 7C). In
particular, improvements become major for large n’s, amounting
to one to two logs. Note that under such conditions, early-
appearing mutants that are weakly resistant to therapy may reach
50% of the viral population at very low densities sometime during
WT’s decline to extinction, albeit without expanding much
further. We therefore modified the definition of fixation to exclude
cases where the entire viral population continues to circulate well
below detectable levels (e.g., 0.01/mL).
The shortened fixation times are not surprising and reflect a
combined influence of acceleration in both WT’s decline and P-
cell expansion. As P cells accumulate, the selective pressure on the
virus builds up and fuels the expansion of resistant strains. P cell
levels are also higher, which further assists those strains. In light of
these factors, it is rather surprising that success rates gradually
improved with further enhancement (Figure 7A). We attribute this
result to a strong counteractive effect of the drastic viral decline
and extinction, which cuts down the de novo generation of highly
resistant strains. It is also worth noting that we further explored
resistance dynamics when proliferation is impaired (av1), as that
may reflect current conditions in gene therapy trials. Therapy
effects on the entire viral population are weakened and slowed
down in this case, and so, as expected, lesser gains from therapy
are associated with weaker and delayed resistance (data not
shown).
The effects of proliferation enhancement resemble those of the
intensification of traditional anti-HIV drugs [16], and, in fact, the
similarity to post-HAART dynamics manifests itself in another
way – it allows the P cells to ‘‘take over’’ the immune system. This
is because sufficiently intense proliferation renders them advanta-
geous even in the absence of HIV, allowing them to populate the
system at the expense of a dwindling U cell reservoir (Figure S2).
Fitter P cells occupy bigger portions of the immune system and
bring it closer to HAART’s homogenous conditions. To
summarize, in the absence of resistance, proliferation enhance-
ment constitutes an important step towards achieving HAART-
like performance. However, when resistance is accounted for, this
strategy may be associated with adverse effects and may prove
beneficial under limited conditions.
Table 1 summarizes each of the above-discussed strategies along
with their impact on treatment outcomes and their parametric
tradeoffs. The first three columns pertain to the qualitative
changes in the figures of merit introduced earlier (Figure 4), where
the success threshold (first column) stands for the minimal n for
which success rates exceed 0.9. The fourth column quantifies the
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changes in the success threshold that correspond to the specified
parameter deviations from the default case.
Discussion
We developed a computational model of HIV-1’s evolutionary
dynamics in the presence of gene therapy to study its long-term
efficacy against the virus. We used the model to quantify the
contributions of key therapy-design parameters and different
treatment strategies to the suppression of viral resistance. We find
that when judiciously designed, gene therapy has the potential to
provide long-term suppression of HIV-1, but meeting this goal
requires highly powerful and robust antiviral genes, which may not
be currently available. In particular, large barriers, ranging from 5
to 9 (depending on therapy parameters), are needed in order to
guarantee that viral suppression below a few percent of pre-
therapy loads lasts at least four years. In addition, gene therapy is
characterized by very slow dynamics in comparison to HAART, as
a consequence of its inherently different mechanism of action. In
particular, it can take about two years to reach a new viral set
point (Figure 2A). This, in turn, makes a long-lasting resistance
control even more critical, if one aims to fully realize the therapy’s
clinical benefits. We find that delaying resistance emergence
merely to the point of reaching a new steady-state viral set point
still requires fairly large genetic barriers, which are only slightly
smaller than those required for a four-year viral control.
We find that two controllable parameters play a key role in
delaying emergence of resistance – the replicative fitness cost
associated with mutation (w) and the therapy’s inhibition factor (e).
Our results demonstrate that intensifying both factors can severely
impair the competence of mutants, and thereby offset the effects of
a significant mutational influx of newly emerging strains (Figure 5).
Our analysis stressed the difference between the ways by which the
two factors w and e take effect, where the mutational fitness cost
acts primarily by hindering viral replication in U cells (Figure 1B)
and the inhibition potency serves to hinder the virus as it replicates
in P cells. This brings into attention a major difference between
gene and traditional therapies, namely that gene therapy leaves a
major fraction of the target cells unprotected. As it turns out, one
can harness this apparent weakness to improve virus control. Our
model predictions support this by showing that small relative
decreases in the average fitness cost per mutation dramatically
improve success rates and delay resistance emergence (Figure 5).
The fitness of mutants in the U cell reservoir, thus, plays an
important role here, and targeting highly conserved regions may
prove to be particularly beneficial for gene therapy. These results
also stress the importance of assessing the fitness of resistant
mutants on cultures of unprotected cells as part of a therapy’s
evaluation.
Our model predicts that sufficiently potent inhibition also
provides a powerful means for preventing the development of
resistance. However, major amplifications in potency are
required in order to achieve benefits that are comparable to
those attainable by minor relative changes in fitness cost
(Figure 5). For example, we find that e’s as low as 1024 can
Figure 7. Effects of proliferation enhancement. Success rates (A),
average fixation times (B), and average viral reductions (C) are shown as
functions of the genetic barrier n (x-axis) for a range of acceleration
factors (a). A factor aw1 stands for a constant boost (of a{1 percent)
to the proliferation rate of P cells in comparison to the proliferation rate
of U cells. Different colors depict different a values, with black depicting
the default case (i.e., no enhancement). Each point summarizes the
outcomes of 500 simulation runs with default parameter values, similar
to Figure 4. Success rates consistently improve as a consequence of
proliferation enhancement (A), but when the virus escapes, fixation is
generally expedited (B). Major improvements in viral reductions take
place before fixation occurs (C).
doi:10.1371/journal.pcbi.1000883.g007
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successfully hamper resistance when combined with a barrier
n~5. Whether such e’s are practical or not is yet to be
determined. Combination therapy, possibly involving different
gene-based techniques, may provide a viable approach to
achieving this goal, and may simultaneously feature large n’s
[4,14]. Nonetheless, its promise depends on the synergistic
interaction between multiple concurrent agents. For example,
potent inhibition may be achieved when their joint potency (e)
amounts to the product of their individual e’s, rather than to
their sum. Importantly, such cumulative effects have not yet
been quantified or validated in the context of gene therapy.
Note also that the importance of highly potent inhibition in
preventing resistance stands in contrast to its negligible
contribution in reducing the sensitive virus load (Figure 2B).
The methods presented above are conventional approaches to
enhancing an antiretroviral treatment’s efficacy, as applied to gene
therapy. However, there are supplementary, less obvious, ways to
boost gene therapy’s performance, which are not possible with
HAART. One such method is to combine multiple therapies across
cells such that the P cells form several sub-populations, where each
population is susceptible to different viral strains. We illustrated
this novel principle through simulations of an abstracted model,
which considers several distinct and equally powerful therapies.
Our results demonstrate that dramatic improvement in success
rates as well as in fixation times can be obtained in this manner
(Figure 4). However, these occur only within a certain window of
genetic barriers. When applied outside this window, improvements
are modest, albeit increasing with increasing number of therapies.
One must therefore reliably characterize the individual therapies
before attempting such a strategy.
It is also interesting to compare the improvements obtained
by splitting therapies to those obtained by increasing the genetic
barrier of a single therapy. We find that the ‘‘winning’’ strategy
varies, depending on the therapy parameters and on the
resistance spectrum of intermediate mutants (Figure 6). The
comparison result particularly depends on e, and on whether it
decreases while n increases. It is reasonable to expect that e
would decrease when n is extended by an insertion of additional
therapeutic genes, as long as they exert their effects via distinct
independent pathways [13,14,41]. In this case, our model
predicts that a single improved therapy will perform at least as
well as a two-therapy approach. If this is not the case, it is
difficult to predict the overall effect on e and which strategy
performs better. An example of the latter case is a combination
of RNAi targets, which is constrained by a maximum tolerable
level of siRNA molecules so as to avoid toxicity [67] and
competition for cellular resources [68]. It is possible that overall
inhibition power may not decrease or may even increase under
such constraints, especially when numerous targets are involved.
Although combination gene therapy has been extensively
studied via experiments over the past few years, we are unaware
of any quantitative results that can be used within our model.
Nonetheless, our analysis points out the key parameters which
need to be quantified in order to compare the two options,
namely, the therapies’ entire spectrum of inhibition potencies.
Gene therapy pressures the virus indirectly by way of a slow P
cell expansion, and its limitations derive from the persistence of U
cells. It has been argued that it could be improved by boosting
proliferation of P cells, such that they outcompete U cells [42]. We
explored the implications of such strategy on resistance dynamics
and observed mixed effects on clinical outcomes: the likelihood of
viral escape is decreased for a narrow range of genetic barriers, but
when escape does occur, it occurs more rapidly than without
enhancement (Figure 7). Overall, both effects are moderate, even
for increases of 30%–40% in proliferative activity. In light of our
results, it is worth noting that this technique is appealing for other
reasons. It induces rapid viral decline, powerfully suppresses WT
virus, and facilitates an extensive re-population of the immune
system with P cells. These major improvements may be associated
with further clinical advantages that are not captured by our
model, such as the recovery of the lymphocyte homeostasis
mechanism, which is believed to be impaired in the presence of
high HIV load [47,69,70].
It is also worthwhile to consider alternative ways for gene
therapy to overcome its limitations. Resorting to hematopoietic
stem cells may not suffice, as simulations we conducted show that
when the infused fraction is small, both approaches are confined
by the same factors and exhibit similar dynamics and efficacies
(data not shown). Only when large fractions are infused, can
meaningful improvements over T-cell-based methods be obtained
(see Figure S3). This is concerning in light of results of recent
clinical trials which indicate that current delivery efficiencies reach
several percent at best [4,41,71]. A potentially promising way to
overcome this limitation is by including a selectable genetic marker
in the antiviral payload that renders the P cells resistant to a
chemotherapeutic agent, to which stem cells are normally
sensitive. It thereby allows for their chemotherapeutic selection
and expansion in vivo. Recent progress in this direction is
encouraging, as substantial selective expansions were observed in
large animal models that were treated with such drugs [72,73,74],
suggesting that these may be used with humans [36,74]. Another
option is to ablate the immune system to make space for the P
cells, and despite its associated risks, is it currently applied in a
number of ongoing clinical trials [75]. From a modeling
perspective, these approaches can be captured by increasing the
fraction of infused stem cells. Our simulations then suggest that the
effects of increased fractions on resistance dynamics are qualita-
tively similar to those of proliferation enhancement, although they
are more modest (see Figure S4). At any rate, a more elaborate
modeling study of stem-cell delivered therapy is required to map
Table 1. Influence of strategies for delaying escape on the average treatment outcome.
Strategy
Success
threshold (n)
Average
fixation time
Average viral
load at fixation
Change in threshold from
default case
Increasing mutational fitness cost (wQ) Q q Q w: 0.95R0.92Rn: 8R6
Increasing inhibition potency (eQ) Q q Q e: 0.01R0.001Rn: 8R6
Combining therapies across cells Q q Q Two therapiesRn: 8R6
Enhancing proliferation (aq) Q Q Q* a: 1R1.1–1.4Rn: 8R7
*The improvements in viral declines by fixation time are major, and significantly exceed those achievable under all other strategies.
doi:10.1371/journal.pcbi.1000883.t001
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the conditions that facilitate considerable responses. This exceeds
the scope of this work but the ideas and models presented here are
readily applicable to this case.
Gene therapy could also potentially be combined with
HAART, so as to benefit from HAART-induced suppression.
The problem with this approach is that HIV is the driving force
behind the expansion of P cells, and their selective advantage
over U cells becomes small with decreasing viral loads [42]. It
thus appears that methods for stimulating P cell proliferation
and/or selection must be developed, such that the P cells can
accumulate independently of the infection, and can then be
effectively combined with HAART. Moreover, these methods
can then leverage on a broad range of agents, including a
variety of RNA-based inhibitors (reviewed in [4]), which may
not propel sufficient cell expansion, but do provide powerful
viral suppression (see Text S1).
A number of simplifying assumptions were incorporated into
our model to retain its generality and tractability. First, we
assumed a fixed incremental effect of each subsequent mutation
on a strain’s phenotype. In reality, individual effects depend on
the actual mutational composition and on order of appearance,
and not all mutational routes yield a viable virus. We therefore
neglected epistatic interactions between mutations and param-
eterized only the average incremental contribution. Second, we
assumed that fitness in P cells is monotonically increasing with a
mutant’s order, and thus mutants of sufficiently high order
always thrive under therapy conditions, and will likely emerge if
generated. Other choices of fitness functions, such as ones that
are non-monotonic or monotonic but assigning lower fitnesses
to all strains, can render such high-order mutants less
competent. Such choices would result in quantitatively different
(more optimistic) emergence statistics, and would mostly depend
on therapy effects on pre-existing mutants. Clearly, once data
for specific therapies become available, the model should be
revised to generate more precise predictions, but at this point,
we focus on capturing the key features involved in the
development of viral resistance, namely, the tradeoffs between
the effects of w and e. These qualitative findings do not depend
on the monotonicity assumption since the same factors
determine the ability of pre-existing strains to outgrow in the
mixed-cell environment. The ideas and analysis pertaining to
combinatorial approaches also apply regardless of the mutants
order and are not function-specific. However, the effects of
proliferation enhancement may differ under non-monotonic
fitness assignments and should be revisited once relevant data
are available.
We also assigned equal mutational fitness costs to replication in
both cell types, which may not always apply. This implies that a
strain is never fitter in P cells than in U cells, and matches recent
experimental findings [23] (see the Methods section). However, if
highly resistant strains replicate better in P cells, our predictions
are over-optimistic - they provide upper bounds on therapy
efficacy and overestimate w’s impact on escape. Another
simplification entails neglecting escape routes that are unlikely
under HAART but may be selected in mixed cell compositions.
Consider, for example, a strain with several mutations that
partially resists therapy and is less fit than WT in U cells. Suppose
that an additional mutation then partially rescues its fitness in U
cells and possibly boosts its resistance as well. If such
compensatory routes exist, they may be selected in environments
where both fitness traits are valuable, and our assumption
excluded such possibilities from consideration. Future work may
further investigate the consequences of such complex fitness
landscapes.
We extended our model to account for the contribution of
recombination to the formation and loss of resistant strains. To
maintain reasonable model complexity and size (especially for
large n’s), we included only simple recombination patterns,
whereby mutations from distinct strains are adjoined, and
mutations are lost during recombination with WT. The
complete details are given in Text S1. We observed very little
quantitative effects on the average treatment outcome, even
under very high recombination rates. Therefore, in the interest
of clarity and simplicity, we omitted recombination from the
model. However, a more detailed treatment of recombination,
particularly in conjunction with epistatic interactions, may
reveal other outcomes, as it was previously shown that
recombination effects are pronounced only in the presence of
epistasis [76,77]. A detailed analysis of this type requires a large
dedicated model (see e.g. the work in [77]) and is not practical
when studying a wide range of genetic barriers as was done
here. Future work may incorporate such detailed mechanisms
for special cases of interest. An additional extension we
considered entailed a homeostasis control of thymus input rates
as opposed to constant rates, but that did not qualitatively affect
our results either (data not shown).
Many of our assumptions can be partially corroborated by in
vitro assays. For example, it is common practice to characterize the
spectrum of potentially resistant mutants through serial passage
experiments. In our case, one can assess the attenuated infection
rates from single-round infection assays [10,44] and reconstruct an
approximate ‘‘resistance profile’’. Similar tests should be conduct-
ed with U cells to quantify both fitness traits. Assays with a mixed
cell population can serve to probe the fitness landscape and
identify mutants that trade their resistance to therapy for
recovered fitness in U cells, as these may be selected in vivo.
Experiments can also help determine the incremental contribu-
tions of single agents in combinatorial settings and whether they
interact multiplicatively, additively, or in any other way. The real
challenge is in extrapolating in vitro findings to clinical settings,
since these do not fully reflect their in vivo counterparts, but yet are
indicative of relative competence among strains. Clinical data are
invaluable to validating our model, but to the best of our
knowledge, sustained P cell expansion has not yet been reported in
any clinical trial. Thus, experimental data from animal models
[41,78] can provide a starting point for better characterizing P cell
expansion and viral suppression, by fitting variations of our model
to clinical measurements.
To summarize, we use a generalized model of HIV gene
therapy to identify both the most effective routes to control the
virus and the critical properties of the antiviral genes that must be
experimentally assessed during the design of such therapies.
Methods
Infection Dynamics
Baseline model. Our model extends upon a commonly used
model of HIV dynamics [16,17], which considers three entities:
healthy target CD4+ T cells (U), productively infected T cells (IU),
and free virions (V). We added two equations that track the
densities of healthy P cells (P) and productively-infected P cells (IP).
These follow similar dynamics, using modified parameter values.
Additionally, we modified the T cell dynamics, such that two
sources contribute to T cell renewal: a constant influx of naı¨ve T
cells from the thymus, and self-proliferation [37,79,80,81]. Since
we consider therapy delivery by T cell infusion, the thymus
contribution is limited to U cells. The proliferation mechanism, in
contrast, encompasses both cell types, and saturates according to
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Michaelis-Menten kinetics. This form was derived in [37] based on
the idea that the activation and proliferation of T cells are
confined by their competition for antigen-presenting sites. Our
formulation also reflects an assumption that the ex vivo
manipulation of P cells did not compromise their proliferative
ability and that they display a normal T cell phenotype.
Importantly, both cell types are assumed to equally contribute to
saturation, thus equally competing for presence in the T cell pool.
In the presence of gene therapy, the model dynamics are governed
by the following equations:
dU
dt
~lz
rU
hzUzP
{dU{kUV
dP
dt
~
rP
hzUzP
{dP{ekPV
dIU
dt
~kUV{dIU
dIP
dt
~ekPV{dIP
dV
dt
~r IUzIPð Þ{cV
ð2Þ
where l is the thymus-input rate, r and h are Michaelis-Menten
constants, d is the lymphocyte death rate, k is the rate at which WT
infects susceptible cells, d is the death rate of infected cells, c is the
virion clearance rate, and r is the rate of virus production from
infected cells. An additional parameter conveys the effects of
therapy on P cells, that is, an inhibition factor e, which attenuates
the rate at which they are infected. If the proliferation of the P cells
is enhanced, the rate is multiplied by an acceleration factor aw1,
yielding a rate ar= hzUzPð Þ. When stem cells are infused, the
thymus input rate of U cells becomes 1{fð Þl, and a thymus input
term of f l is added to the P cells’ equation, where f is the fraction
of gene-modified stem cells.
The efficacy of early-stage inhibitory genes may be further
enhanced by way of combination with late-stage inhibitory genes
[12,82]. When combined with a perfect viral production suppressor,
the virus dynamics are governed by dV=dt~rIU{cV . Steady-
state analysis was carried out for this ideal case, which lends itself to
simple analytical results. This model has three steady states:
uninfected in the absence of therapy (V~0, P~0), infected in
the absence of therapy (V=0, P~0), and infected in the presence
of therapy (V=0, P=0). Since the viral load maintains the same
ratio relative to the infected U cell density in all three cases (i.e.,
V=IU~ r=cð Þ), we compare the infected cell densities (IU ) between
the latter two states, instead of the viral loads. Specifically, we
have I0
U
~l=dzr
.
~khzd
 
{d
.
~k before therapy and
IT
U
~l= d(1{e)½  after therapy, where ~k~kr=c is a generalized
infection rate combining viral infectivity, production, and clearance
rates.
Suppression gain. It is clear from the above expression for
IT
U
that the virus is not eradicated unless l~0. Otherwise, the viral
suppression gain, or the ratio of cells infected in the absence vs. in
the presence of therapy, is given by
G~
I0U
ITU
~I0Ud
1{e
l
 
: ð3Þ
Since d is well-characterized to be between 0.3 and 0.7 per day
[38,83] and the pre-therapy infected-cell levels are maximally
on the order of a few tens per mL [84], the maximal suppression
gain (when e&0) is approximately 10-fold greater than 1=l. If
we assume that l supplies no more than a few percent of the
natural T-cell mortality in adults [45], this amounts to a
contribution on the order of 0.01*0.01*1000 = 0.1 cells/
[mL*day] (i.e., 1% of a death rate of 0.01/day multiplied by
an average T-cell level of a healthy individual). Combining these
estimates yields a maximal suppression gain of approximately
two logs. To realize gains comparable to HAART [40], the
thymus’ relative contribution should be considerably lower than
a few percent. We used Eq. (3) to illustrate the dependence of G
on e and l (Figure 2B–2C), while keeping the pre-therapy
conditions fixed so as to allow for a fair comparison (see Text S1
for details).
At this point, we note that our choice of the baseline model was
guided by a comparison we conducted between this model and a
model of a different type of protection, whereby the genes inhibit
expression of viral proteins in infected cells rather than infectivity.
Such inhibition confers a selective advantage to the infected P cells
in the form of extended life spans, and may additionally suppress
virus production [20,22]. Currently, a wide array of suitable
methods exists, with some already being tested in clinical trials
(reviewed in [4]). We found that for a wide range of relevant e
values, viral-entry inhibitors are more advantageous than gene-
expression inhibitors (see Text S1 for details and for conditions
under which the latter approach may be practical).
Evolutionary Dynamics
Multistrain model. We extended the baseline model to
account for the dynamics of a collection of viral strains, displaying
a range of resistance capabilities to therapy. Three equations
describe the dynamics of each mutant strain M, tracking the
densities of infected U cells (IUM ), infected P cells (IPM ), and free
virions (M), as follows:
dIUM
dt
~wMkUMzmFU (M){dIUM
dIPM
dt
~eMwMkPMzmFP(M){dIPM
dM
dt
~r IUMzIPM
	 

{cM
ð4Þ
where wM is a replicative fitness cost associated with mutating from
WT, and eM is the infectivity inhibition factor, expressing altered
protection against strain M. The terms mFU (M) and mFP(M)
represent the mutation of other strains into M during reverse
transcription, where m is the rate of point mutation at any resistance-
conferring site, and FU (M), FP(M) stand for the density of U and P
cells that are newly infected with strains that may precede M,
respectively. The infection terms wMkUM and eMwMkPM were
subtracted from the susceptible-cell equations. Note that we assumed
that viral production rates are unaffected by the mutational process,
which is more likely to alter the fusion, binding, or integration
capacities of the virus [10]. Our model formulation also neglects the
loss of infected cells due to mutation into other strains. In preliminary
simulations we observed that inclusion of such loss had little effect on
our results.
Stochastic events. We supplemented Eq. (2) with a
stochastic module that accounts for the randomness taking place
during mutant appearance [18]. We followed previous approaches
to implementing a stochastic counterpart of our model [85,86],
which takes effect whenever a species’ density falls below a
predefined threshold (similar to [86]). Additional details are found
in Text S1.
Fitness cost. We modeled the replication fitness of a mutant
as dependent on the number of resistance-conferring sites that are
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mutated away from their WT form. We refer to this number as the
number of resistance mutations, or the order of the mutant. We
assumed that fitness effects are multiplicative [53], implying a
fitness cost of wM~w
m for an m-order mutant, where w is a fixed
average fitness cost per mutated site. We also assumed that this loss
applies to infection of both U and P cells. This implies that for P
cells, wmk sets an upper limit on the infection rates of m-order
mutants, as these may be further downgraded by a factor of
eMƒ1. In other words, a strain cannot be fitter in P cells than in U
cells. Similar relations, where mutants display weaker replication
in P cells than in U cells, were recently observed in vitro for RNAi-
escape mutants [23], and motivated our modeling choice.
Nevertheless, this assumption may be optimistic, in the sense
that sufficient adaptation may result in highly resistant strains that
replicate better in P cells than in U cells. Our model can be readily
adapted to reflect such conditions, but in the lack of relevant gene
therapy data, we assumed that resistance manifests itself only
through overcoming inhibition.
Infectivity inhibition. We assumed that a mutant’s resistance
level depends on the number of resistance mutations, with each
additional mutation contributing equally and multiplicatively to
overall resistance. We therefore spaced the inhibition factors of
intermediate mutants between the WT and full-resistance levels, as
follows. If n mutations confer full resistance, then the inhibition
factor of an m-order mutant (0ƒmƒn) is set to eWTDm,
where D~ 1=eWT½ 
1=n, and eWT stands for WT inhibition.
Therefore, the fully-resistant n-order mutant experiences no
inhibition by P cells, and is equally competent in both cell types.
Note that such scheme disregards epistatic effects and is equivalent
to a linear change in viral infectivity on a logarithmic scale.
Almost no quantifiable data is available on the efficacy of gene
therapies against increasingly resistant mutants, making it difficult
to accurately model the changes in e. However, the reasoning
behind our choice is twofold. First, if several protective genes are
combined, we assume their inhibitory effects are multiplicative.
Partial resistance can then be thought of as escaping a subset of
therapies [86]. Second, recent experiments with traditional
antiretroviral therapies support a similar multiplicative form of
declining efficacy with mutation accumulation [54,77,87]. In the
context of gene therapy, we are aware of one recent work that
partially quantified the infectivity inhibition of intermediate
mutants under in vitro conditions [10], indicating that single-
mutation contributions are non-additive and nonlinear, thus
further supporting our modeling assumption. Moreover, our
understanding of the mechanism of HIV’s escape from RNA-
mediated inhibition [11,22], where potency correlates with the
goodness of match between the genome and the target sequence,
further motivates our choice.
Mutations. Our model accounts only for first-order accrual
of point mutations, that is, each strain may be added at most a
single point mutation at each ODE integration step (Figure 1B).
For simplicity, we also excluded the reverse mutational process
(i.e., towards less-resistant strains), as its contribution is minor due
to much-lower densities of higher-order mutants. Our
assumptions thus imply that an m-order mutant may be directly
preceded by each of the (m21)-order mutants whose mutated
sites form a subset of its m sites. For example, if M123 is 3-point
mutations away from WT (the subscripts label the mutated sites),
then its predecessors are the 2-order mutants M12, M13, and
M23.
Complexity reduction. The above assumptions allude to
perfect symmetry among same-order mutants, as any m-order
mutant experiences a fitness cost factor of wm and an inhibition
factor of eWTD
m. We exploited it to obtain a smaller and simplified
model. For each m, we grouped all m-order strains into one class
and summed the various densities over all class mutants. The
resulting equations appear as follows:
dIU
M(m)
dt
~wmkUM(m)z
(n{mz1)m wm{1kUM(m{1)
 
{dIU
M(m)
dIP
M(m)
dt
~eWTD
mwmkPM(m)z
(n{mz1)m eWTD
m{1wm{1kPM(m{1)
 
{dIP
M(m)
dM(m)
dt
~r IU
M(m)
zIP
M(m)
 
{cM(m)
ð5Þ
where n is the order of the fully-resistant mutant, and IUM(m) ,
IPM(m) , and M(m) are the aggregate densities per m. The
multiplicity coefficient (n2m+1) accounts for the affiliation of
each (m21)-order strain with the predecessor sets of multiple m-
order strains. For example, when n= 3, the mutant M1 contributes
to the influx of both M12 and M13 (m= 2), whereas WT
contributes to M1, M2, and M3 (m= 1). The symmetric model
has 3(nz1)z2 equations, compared to 3|2nz2 in the general
case. Such complexity reduction becomes significant when
considering the large n’s required for effective gene therapy, and
is crucial for tackling the more elaborated scenario of multiple P-
cell populations.
Heterogeneous Protected-Cell Composition
We assumed the availability of two distinct protective-gene
cassettes, which target different viral components, and thereby give
rise to two non-overlapping sets of resistance-conferring sites, S1
and S2. We further assumed that both cassettes, hereafter called
Therapy 1 and Therapy 2, are equally powerful, that is, they have
the same starting inhibition factor eWT , same n, and same
intermediate inhibition factors. When used jointly, there is no
cross-resistance between them. That means that the inhibition
exerted by Therapy 1 (2) on a given strain depends solely on the
number of mutated sites in S1 (S2), and is independent of the
mutated sites in S2 (S1). For a given n, there are now 2n
resistance-conferring sites, contained in S1~ 1, . . . ,nf g and
S2~ nz1, . . . ,2nf g. A strain that shares m mutated sites with
S1 and l mutated sites with S2 will encounter inhibition factors of
e1~eWTD
m and e2~eWTD
l by Therapies 1 and 2, respectively.
The fitness cost factor is determined by the total number of
mutated sites, and equals wmzl .
Symmetric form. A straightforward implementation of such
model encompasses 22n strains and 4|22nz3 equations. As
before, we exploited the inherent symmetry and classified the
strains into N~
nz2
n
 
resistance-phenotype classes. In
particular, each class is identified by a pair m,lf g (0ƒm,lƒn),
and all its members share m sites with one therapy’s set and l sites
with the other set (see Text S1 for details and equations). The
model has 3|Nz2 equations (which is on the order of n2) and
takes a similar form to Eq. (4), with modified inhibition and fitness
cost factors, predecessor classes, and multiplicity coefficients. The
major reduction in model size ensured the tractability of the model
and the simulations for relevant n values.
Model Parameters and Initialization
We used the following parameter values based on prior studies
[70,83,84,86,88,89,90]: the death rate of healthy CD4+ cells,
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d~0:015 1/day; the death rate of infected cells, d~0:5 1/day; the
viral clearance rate, c~6 1/day; the mutation rate, m~3|10{5
per base per replication. The virion production and infection rates
are not well characterized and were set to r~120 virions/
[cell*day] and k~0:00008 mL/[virion*day], respectively, to
match observed viral dynamics in untreated infections. We set
the T-cell renewal parameters to yield realistic T cell densities in
the absence of infection (1,000–1,300 cells/mL) and realistic pre-
therapy viral loads (102–103 virions/mL) [16,38,90]. We also
assumed that the thymus regenerates 1% of the total cell loss,
implying the following parameter values: l~0:2 cells/[mL*day],
r~20 cells/[mL*day], and h~90 cells/mL. We also tested
numerous other parameter values and did not observe qualita-
tively different results. A species was considered extinct if its
density fell below 3|10{9 per mL, corresponding to one entity per
body, based on 5 liters of blood which contain 1%–2% of the
entire susceptible cell population [86]. Its dynamics were treated
stochastically as long as its density did not exceed 3|10{7 per mL.
The default values of therapy-related parameters were w~0:95
and e~0:01 [44]. The fraction of infused P cells was 1% of the
entire U cell population at the time of infusion (day 0) [5,21]. The
system was first brought to steady state, where simulations over a
400-day period ensured convergence to a HIV set point. Our
parameter choices result in pre-existing strains with one, two, and
three resistance mutations. Clinical experience suggests that
double-point mutations are likely to exist in sufficient levels in
untreated HIV patients, but it is not known if triple-point
mutations are sufficiently abundant as well. Our model may thus
be too ‘‘pessimistic’’, and under less conservative parameter
choices will result in less stringent requirements for a successful
gene therapy.
Supporting Information
Figure S1 Stochastic effects that dominate mutant appearance
result in large variations in fixation times. Effects of increasingly
larger genetic barriers n (x-axis) on the time to fixation (y-axis),
which is the time required for the resistant strains to reach 50% of
the viral population, measured from therapy initiation at day 0.
Each marked point represents the average of at least 50 simulation
runs in which fixation occurred within four years from therapy
initiation. The bars correspond to one standard deviation. Each
curve depicts the aggregate outcome for different parameter
choices, where w is a fixed average fitness cost per mutated site
and e is the therapy’s inhibition factor (see the Methods section for
more details). All other parameters were set to their default values.
The figure shows that larger n’s are associated with increasing
variation in fixation time. This is because the stochastic
fluctuations of newly emerging mutants build up along the
evolutionary process. When n becomes larger, more mutations
are needed in order to confer sufficient resistance, and hence the
time to fixation of such highly-mutated strains depends on the
appearance times of their preceding mutants, which experience
random drift as well.
Found at: doi:10.1371/journal.pcbi.1000883.s001 (0.05 MB PDF)
Figure S2 Infection dynamics under enhanced proliferation of
protected cells. System dynamics in the absence of viral resistance
and when the P cells have a proliferative advantage over the U
cells. Enhanced proliferation of P cells was modeled as a constant
percentage increase in their proliferation rate compared to the U
cells’ proliferation rate. Simulations were performed with default
parameter values and with 30% increase in the P cells’
proliferation rate (see the Methods section for more details).
Enhanced proliferation expedites P cell accumulation and viral
decline and drives the virus to extinction. It additionally results in
higher P cell densities, allowing them to increase their relative
proportion in the immunity system on the expense of a declining U
cell population.
Found at: doi:10.1371/journal.pcbi.1000883.s002 (0.16 MB PDF)
Figure S3 Infection dynamics following infusion of a large
fraction of protected stem cells. System dynamics in the absence of
viral resistance and when protected stem cells are infused to the
patient. Stem cell infusion was modeled by an addition of a
constant thymus-export term to the renewal of P cells, and by a
reduction in the rate of thymus export to the U cell compartment.
The modified terms are determined by the fraction of the
protected stem cells in the bone marrow (see the Methods section).
The simulation corresponds to 90% of the stem cells being
protected, and to a bone-marrow contribution of 10%, and was
performed with default infection and therapy parameter values.
Increasing the fraction of protected stem cells expedites P cell
accumulation and viral decline, and allows for higher P cell
densities to be reached, such that their relative proportion in the
immunity system is increased on the expense of the declining U
cell population.
Found at: doi:10.1371/journal.pcbi.1000883.s003 (0.06 MB PDF)
Figure S4 Effects of increasing the fraction of protected stem
cells. Success rates (A), average fixation times (B), and average viral
reductions (C) are shown as functions of the genetic barrier n (x-
axis) for a range of infused fractions. The parameter f corresponds
to the fraction of stem cells that are protected (see the Methods
section), and different colors depict different f values. Each point
summarizes the outcomes of 500 simulation runs with default
parameter values. Success rates gradually improve with increasing
protected fractions (A), but when the virus escapes, fixation is
generally expedited (B). The viral reductions obtained by the time
of fixation are also improved (C).
Found at: doi:10.1371/journal.pcbi.1000883.s004 (0.03 MB PDF)
Text S1 Additional details about the model and simulations.
Found at: doi:10.1371/journal.pcbi.1000883.s005 (0.43 MB
DOC)
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